Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

David A. Hyman, MD, JD, on Inclusive Shared Savings

Varsha Gandhi, PhD, on Ibrutinib

Advertisement

Advertisement




Jun
29
Today In Oncology
Paving New ROADS in the Treatment of Brain Metastases With Implanted Tile-Based Radiation Therapy
I Miss My Life
Existing Cardioprotective Agents Provide Limited Benefits for Patients With Cancer
First-Line Avelumab Plus Methotrexate in Low-Risk Gestational Trophoblastic Tumors
CNS Prophylaxis With High-Dose Methotrexate in Ultra–High-Risk Large B-Cell Lymphoma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo